JANUMET, a combination of Sitagliptin 50 mg / Metformin 500 mg is a line extension of the Merck & Co. block buster brand Januvia. The two ingredients of Janumet work with complementary mechanisms of action to improve glycemic control in patients with Type 2 Diabetes Mellitus.
Launched in Pakistan on September 26, 2010, Janumet was received with enthusiasm by the top Physicians, Endocrinologists and Diabetologists in Pakistan. OBS is conducting Doctor Group Meetings across Pakistan to establish the concept of Fixed Dose Combinations. According to EASD and AACE guidelines, combination therapy with Sitagliptin plus Metformin is definitely superior to monotherapy.